Cáncer de mama y osteoporosis

  • Jorge P. Suárez Universidad Nacional de Colombia.
  • William Onatra H. Universidad Nacional de Colombia,
  • Jacinto A. Sánchez Universidad Nacional de Colombia,

Resumen

Se presenta un caso de una mujer de 54 años, con antecedentes de mastectomía izquierda por Ca. canalicular Estado III, con Osteoporosis O que no ha respondido a la terapia a base de calcio y fluor, proponiéndose la posibilidad de iniciar terapia hormonal de reemplazo.

Biografía del autor/a

Jorge P. Suárez, Universidad Nacional de Colombia.

Residente III, Programa de postgrado, Departamento de Obstetricia y Ginecología, Universidad Nacional de Colombia.

William Onatra H., Universidad Nacional de Colombia,

Profesor Asistente, Departamento de Obstetricia y Ginecología, Universidad Nacional de Colombia, Clínica de Menopausia. Instituto Materno Infantil- Santafé de Bogotá.

Jacinto A. Sánchez, Universidad Nacional de Colombia,
Profesor Asistente, Departamento de Obstetricia y Ginecología, Universidad Nacional de Colombia, Clínica de Menopausia. Instituto Materno Infantil- Santafé de Bogotá.

Citas

Christiansen C., Riis B. "Post-menopausal Osteoporosis" Fagerstien 8, 2950 Vedback Dinamarca, 1990.

Overgaard R. " 'Effects of intranasal synthetic salmon calcitonin on bone breakdown" . Br. Med. J. 1989; 299:477.

Current Perspectives in the Management of the Menopausal and Postmenopausal patient. Symposium. Am. J. Obstet Gynecol 1987; 156: 1353.

Hodsman B., Drost D. "The response of vertebral bone mineral density during the treatment of .

Gambrell R.D. Use of progestogen therapy. A m. J. Obstet Gynecol. 1987; 156: 130-131.

Lobo R. , Singer M. "Depo-Medroxyprogester one Acetate compared with conjugated estrogens for the treatment of Post-menopausal women. Obstet Gynecol 1984; 63:1.

Fornander R, Rutqvist LE, Sjoberg HE, et al. Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncoll990; 8:1019-1024.

Love RR, Mazess RB, Tonney DC, et al. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988; 12:279-302.

Barrett-Conner E, Bush TI. Estrogen replacement and coronary heart disease. Cardiovasc Clin 1989; 19:159-172.

Love RR, Newcomb PA, Weibe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. N Natl Cancer Inst 1990; 82 :1327-1 332.

Wile AG. DiSaia PJ . Hormones and breast cancer. Am J Surg 1989; 157: 438-442.

Dupont WD, Page DI. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991; 15 1:67-72.

Steimber KK, Thacker SB, Smith SS et all. A meta-anlysis of the effect of estrogen replacement therapy on the risk of breast cancer, JAMA 1991:266:1362- 1365.

Brener H, Engelsman B. Stegmaier C et all. Clinical Epidemiology of bilateral breast cancer. Cancer 1993; 72:3629-3635.

Wile AG, Opfell RW, Margilet DA. Hormone Replacement therapy in previously treatet breast cancer patients . Arn J Surg 1993; 165 :372-375.

Buller RE. Hormone rep replacement therapy following ginecologic cancer. Post graduate Obstet Gynecol 1993; 13:1-5.

Creasman WT. Hormone replacement therapy in breast cancer. Lancet 1993; 342: 1232.

Marchant DJ. Estrogen-replacement therapy in breast cancer. Cancer 1993; 7 1:2 169-2176.

Di Saia PJ. Hormone- replacement therapy in patients with breast cancer: a reappraisal. Cancer 1993 ; 71: J 490- 1500

Publicado
1994-12-30
Sección
Artículos Originales